Current Ozempic Shortage Status
The Ozempic (semaglutide) shortage in the US, driven by high demand for weight loss use beyond its approved type 2 diabetes indication, began in late 2022. Novo Nordisk reports it has resolved the shortage for most doses as of October 2024, with all strengths (0.25 mg, 0.5 mg, 1 mg, and 2 mg) now available at pharmacies without restrictions.[1][2] The FDA removed Ozempic from its drug shortage list on October 4, 2024, confirming normalized supply.[3]
Why the Shortage Happened and Recent Fixes
Demand surged over 300% from 2022 to 2023 due to off-label weight loss prescriptions, outpacing manufacturing. Novo Nordisk expanded production at facilities in Denmark and the US, added new suppliers, and limited doses to type 2 diabetes patients earlier in 2024. These steps restored supply by mid-2024, ending backorders.[1][4]
Will Shortages Return?
Novo Nordisk expects sustained supply through 2025, supported by investments in new plants and capacity doubling since 2022. However, ongoing demand growth—fueled by telehealth and social media—could pressure stocks if production lags. No new shortages are forecasted, but regional or dose-specific issues have occurred sporadically in 2024.[2][5]
Impact on Patients and Alternatives During Shortage
Patients faced delays of weeks to months; many switched to compounded semaglutide (custom-made versions) or alternatives like Wegovy (higher-dose semaglutide, also from Novo), Mounjaro (tirzepatide from Eli Lilly), or metformin/insulin for diabetes. Compounding filled gaps but raised safety concerns due to lack of FDA approval; the FDA now limits compounded versions post-shortage.[3][6]
Related Shortages: Wegovy and Other GLP-1 Drugs
Wegovy, Ozempic's sister drug for obesity, faced intermittent shortages into late 2024 but is improving with starter dose availability. Mounjaro and Zepbound (tirzepatide) have seen their own supply strains from demand, with FDA listings active as of October 2024.[3][7]
Looking Ahead: Supply Timeline and Competition
Novo aims for full supply stability by early 2025. Biosimilars won't arrive until at least 2031 due to patent protections (e.g., US Patent 8,129,343 expires 2032).[8] Eli Lilly's oral orforglipron (phase 3 trials) could compete by 2026-2027 if approved.[9]
Sources
[1] Novo Nordisk Supply Update (October 2024)
[2] Novo Nordisk Earnings Call Q3 2024
[3] FDA Drug Shortages List
[4] Novo Nordisk Capacity Expansion Announcement
[5] ASHP Ozempic Shortage Tracker
[6] FDA Compounded Semaglutide Alert
[7] FDA Tirzepatide Shortage Status
[8] DrugPatentWatch: Ozempic Patents
[9] Eli Lilly Pipeline Update